This review aims to determine benefits and harms of daratumumab in addition to antineoplastic therapy compared to antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
This is a protocol.
This review aims to determine benefits and harms of daratumumab in addition to antineoplastic therapy compared to antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
This is a protocol.